IDEXX Laboratories Inc. (IDXX)

IDEXX Laboratories Inc. (IDXX $670.46)
- $670.46 P/E (TTM): 53.66X Cap: $53.53B
- View IDXX Profile
- View Questions on IDXX

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Intuitive Surgical Inc. (ISRG $504.22)
- $504.22 P/E (TTM): 67.05X Cap: $178.74B
- View ISRG Profile
- View Questions on ISRG
Vertex Pharmaceuticals Incorporated (VRTX $469.90)
- $469.90 P/E (TTM): 33.26X Cap: $119.22B
- View VRTX Profile
- View Questions on VRTX
AbbVie Inc. (ABBV $223.01)
- $223.01 P/E (TTM): 168.27X Cap: $394.14B
- View ABBV Profile
- View Questions on ABBV
Johnson & Johnson (JNJ $227.25)
- $227.25 P/E (TTM): 21.94X Cap: $547.51B
- View JNJ Profile
- View Questions on JNJ
Eli Lilly and Company (LLY $1,037.15)
- $1,037.15 P/E (TTM): 50.1X Cap: $980.50B
- View LLY Profile
- View Questions on LLY
Merck & Company Inc. (MRK $110.27)
- $110.27 P/E (TTM): 14.32X Cap: $273.69B
- View MRK Profile
- View Questions on MRK
iShares Biotechnology ETF (IBB $172.43)
- $172.43 P/E (TTM): 20.63X Cap: $8.51B
- View IBB Profile
- View Questions on IBB
IDEXX Laboratories Inc. (IDXX $670.46)
- $670.46 P/E (TTM): 53.66X Cap: $53.53B
- View IDXX Profile
- View Questions on IDXX
Halozyme Therapeutics Inc. (HALO $71.71)
- $71.71 P/E (TTM): 15.1X Cap: $8.43B
- View HALO Profile
- View Questions on HALO
Incyte Corporation (INCY $100.07)
- $100.07 P/E (TTM): 17.11X Cap: $19.64B
- View INCY Profile
- View Questions on INCY
Catalyst Pharmaceuticals Inc. (CPRX $24.30)
- $24.30 P/E (TTM): 14.29X Cap: $2.98B
- View CPRX Profile
- View Questions on CPRX
Gilead Sciences CDR (CAD Hedged) (GILD $28.99)
- $28.99 P/E (TTM): 367.68X Cap: $239.83B
- View GILD Profile
- View Questions on GILD

Q: We have accumulated 11 healthcare stocks and 1 ETF, While LLY and ISRG are at half positions the rest are at initial 25% positions. Please advise [help!] us get to a more concentrated portfolio with a 3+ year horizon for reasonable opportunities in healthcare

Read Answer Asked by sam on January 13, 2026

Adobe Inc. (ADBE $293.25)
- $293.25 P/E (TTM): 17.78X Cap: $120.37B
- View ADBE Profile
- View Questions on ADBE
Accenture plc Class A (Ireland) (ACN $263.64)
- $263.64 P/E (TTM): 21.5X Cap: $174.11B
- View ACN Profile
- View Questions on ACN
Nike Inc. (NKE $61.81)
- $61.81 P/E (TTM): 32.1X Cap: $91.50B
- View NKE Profile
- View Questions on NKE
Thermo Fisher Scientific Inc (TMO $578.61)
- $578.61 P/E (TTM): 34.21X Cap: $217.38B
- View TMO Profile
- View Questions on TMO
TELUS Corporation (T $19.00)
- $19.00 P/E (TTM): 24.36X Cap: $29.41B
- View T Profile
- View Questions on T
IDEXX Laboratories Inc. (IDXX $670.46)
- $670.46 P/E (TTM): 53.66X Cap: $53.53B
- View IDXX Profile
- View Questions on IDXX

Q: Dear 5i,

I have a diverse portfolio with stocks and ETFs. Most of my portfolio is doing well. Want to know your thoughts about a few of my holdings that are not doing so well - Adobe, Nike, Accenture, TMO, IDXX and Telus.

What are your thoughts? Should I replace these with a US ETF or hold on. Thanks for your valuable advice as always.

Read Answer Asked by Alka on November 26, 2025

IDEXX Laboratories Inc. (IDXX $670.46)
- $670.46 P/E (TTM): 53.66X Cap: $53.53B
- View IDXX Profile
- View Questions on IDXX

Q: I bought half a position in IDEXX about a month ago, they recently had about a 25% pop after their results. Would you be comfortable for me adding to my position here?

Read Answer Asked by Andrew on August 11, 2025